Kyowa Hakko Kirin Co., Ltd. has initiated a phase III clinical study evaluating KHK7580 for secondary hyperparathyroidism patients receiving hemodialysis in Japan. Kyowa Hakko Kirin conducts this study to evaluate the efficacy and safety of KHK7580 orally administered once daily for 30 weeks in subjects with secondary hyperparathyroidism receiving hemodialysis in a randomized, double-blind, intra-subject dose-adjustment, parallel-group design with cinacalcet hydrochloride as an active control. KHK7580 is a small molecular compound produced by Mitsubishi Tanabe Pharma Corporation.

Kyowa Hakko Kirin signed a license agreement of KHK7580 with Mitsubishi Tanabe Pharma for the rights to cooperative research, develop, market and manufacture the product in Japan and some part of Asia on March 2008.